Down-regulation of hepcidin in porphyria cutanea tarda

Blood

Volumn 112, Issue 12, 2008, Pages 4723-4728

  Ajioka, Richard S ^a   Phillips, John D ^a   Weiss, Robert B ^a   Dunn, Diane M ^a   Smit, Maria W ^b   Proll, Sean C ^b   Katze, Michael G ^b   Kushner, James P ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEMOJUVELIN; HEPCIDIN; IRON; ANTIMICROBIAL CATIONIC PEPTIDE; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DOWN REGULATION; EXON; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; IRON OVERLOAD; LIVER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PORPHYRIA CUTANEA TARDA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; COMPARATIVE STUDY; DNA MICROARRAY; GENETICS; LIVER DISEASE; MIDDLE AGED; PHYSIOLOGY; SIDEROSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMICROBIAL CATIONIC PEPTIDES; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INFANT; LIVER DISEASES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PORPHYRIA CUTANEA TARDA; SIDEROSIS; YOUNG ADULT;

EID: 58149374693     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-138222     Document Type: Article

References (51)

1. Bulaj ZJ, Phillips JD, Ajioka RS, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood. 2000;95:1565-1571.
2. Phillips JD, Bergonia HA, Reilly CA, Franklin MR, Kushner JP. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci U S A. 2007;104: 5079-5084.
3. Phillips JD, Jackson LK, Bunting M, et al. A mouse model of familial porphyria cutanea tarda. Proc Natl Acad Sci U SA. 2001;98:259-264.
4. Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet. 1997;349:321-323.
5. Elder GH, Worwood M. Mutations in the hemochromatosis gene, porphyria cutanea tarda, and iron overload. Hepatology. 1998;27:289-291.
6. Feder JN, Gnirke A, Thomas W, et al.A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996; 13:399-408.
7. Jouanolle AM, Fergelot P, Gandon G, Yaouanq J, Le Gall JY, David V.Acandidate gene for hemochromatosis: frequency of the C282Y and H63D mutations. Hum Genet. 1997;100:544-547.
8. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997;34:275-278.
9. PietrangeloA. Non-HFE hemochromatosis. Hepatology. 2004;39:21-29.
10. Roetto A, Camaschella C. New insights into iron homeostasis through the study of non-HFE hereditary haemochromatosis. Best Pract Res Clin Haematol. 2005;18:235-250.
11. Wallace DF, Subramaniam VN. Non-HFE haemochromatosis. World J Gastroenterol. 2007;13: 4690-4698.
12. Olynyk JK, Cullen DJ,AquiliaS, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999;341:718-724.
13. Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med. 2000;343: 1529-1535.
14. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G-> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002;359:211-218.
15. Asberg A, Hveem K, Kannelonning K, Irgens WO. Penetrance of the C28Y/C282Y genotype of the HFE gene. Scand J Gastroenterol. 2007;42: 1073-1077.
16. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358:221-230.
17. Biasiotto G, Belloli S, Ruggeri G, et al. Identification of new mutations of the HFE, hepcidin, and transferrin receptor 2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload. Clin Chem. 2003;49:1981-1988.
18. Merryweather-Clarke AT, Cadet E, Bomford A, et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet. 2003;12:2241-2247.
19. Le Gac G, Scotet V, Ka C, et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of theous phenotype. Hum Mol Genet. 2004;13: 1913-1918.
20. Biasiotto G, Roetto A, Daraio F, et al. Identification of new mutations of hepcidin and hemojuvelin in patients with HFE C282Y allele. Blood Cells Mol Dis. 2004;33:338-343.
21. Fleming RE, Holden CC, Tomatsu S, et al. Mouse strain differences determine severity of iron accumulation in Hfe knockout model of hereditary hemochromatosis. Proc Natl Acad Sci U SA. 2001;98:2707-2711.
22. Dupic F, Fruchon S, Bensaid M, et al. Inactivation of the hemochromatosis gene differentially regulates duodenal expression of iron-related mRNAs between mouse strains. Gastroenterology. 2002; 122:745-751.
23. Scheuer PJ, Williams R, Muir AR. Hepatic pathology in relatives of patients with haemochromatosis. J Path Bacteriol. 1962;84:53-64.
24. Edwards CQ, Carroll M, Bray P, Cartwright GE. Hereditary hemochromatosis: diagnosis in siblings and children. N Engl J Med. 1977;297:7-13.
25. Guttridge MG, Thompson J, Worwood M, Darke C. Rapid detection of genetic mutations associated with haemochromatosis. Vox Sang. 1998; 75:253-256.
26. Kent WJ, Sugnet CW, Furey TS, et al. The human genome browser at UCSC. Genome Res. 2002; 12:996-1006.
27. Flanigan KM, von NiederhausernA, Dunn DM, Alder J, Mendell JR, Weiss RB. Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet. 2003;72:931-939.
28. Nickerson DA, Tobe VO, Taylor SL. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res. 1997;25:2745-2751.
29. Phillips JD, Parker TL, Schubert HL, Whitby FG, Hill CP, Kushner JP. Functional consequences of naturally occurring mutations in human uroporphyrinogen decarboxylase. Blood. 2001;98:3179-3185.
30. Roetto A, Totaro A, Cazzola M, et al. Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet. 1999;64:1388-1393.
31. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004;36:77-82.
32. Nemeth E, Preza GC, Jung CL, Kaplan J, Waring AJ, Ganz T. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood. 2006;107:328-333.
33. van Dijk BA, Kemna EH, Tjalsma H, et al. Effect of the new HJV-LL165X muation on penetrance of HFE. Blood. 2007;109:5525-5526.
34. Lee PL, Barton JC, Brandhagen D, Beutler E. Hemojuvelin (HJV) mutations in persons of European, African-American and Asian ancestry with adult onset haemochromatosis. Br J Haematol. 2004;127:224-229.
35. Wallace DF, Dixon JL, Ramm GA, Anderson GJ, Powell LW, Subramaniam N. Hemojuvelin (HJV)-associated hemochromatosis: analysis of HJV and HFE mutations and iron overload in three families. Haematologica. 2005;90:254-255.
36. Fujita N, Sugimoto R, Takeo M, et al. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med. 2007;13: 97-104.
37. Nagashima M, Kudo M, Chung H, et al. Regulatory failure of serum prohepcidin levels in patients with hepatitis C. Hepatol Res. 2006;36:288-293.
38. Nishina S, Hino K, Korenaga M, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology. 2008;134:226-238.
39. Trinder D, Ayonrinde OT, Olynyk JK. HCV, iron, and oxidative stress: the new choreography of hepcidin. Gastroenterology. 2008;134:348-351.
40. Tavill AS, Qadri AM. Alcohol and iron. Semin Liver Dis. 2004;24:317-325.
41. Harrison-Findik DD, Klein E, Crist C, Evans J, Timchenko N, Gollan J. Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. Hepatology. 2007;46:1979-1985.
42. Harrison-Findik DD, Schafer D, Klein E, et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem. 2006;281:22974-22982.
43. Bridle K, Cheung TK, Murphy T, et al. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res. 2006;30:106-112.
44. Bulaj ZJ, Franklin MR, Phillips JD, et al. Transdermal estrogen replacement therapy in postmenopausal women previously treated for porphyria cutanea tarda. J Lab Clin Med. 2000;136:482-488.
45. Kubo M, Hostetler KY. Metabolic basis of diethylaminoethoxyhexestrol- induced phospholipid fatty liver. Am J Physiol. 1987;252:E375-E379.
46. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology. 2001;121:710-723.
47. Lefkowitch JH. Hepatobiliary pathology. Curr Opin Gastroenterol. 2003;19:185-193.
48. Seki S, Kitada T, Sakaguchi H. Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatol Res. 2005;33:132-134.
49. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in nonalcoholic fatty liver diseases. J Hepatol. 2002;37: 56-62.
50. George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol. 2003;39:756-764.
51. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemo-chromatosis and the liver as a regulator of body iron homoeostasis. Lancet. 2003;361:669-673.